동반진단 경쟁 분석(2026년)

The companion diagnostics competitive landscape represents the evolving ecosystem of diagnostic developers, life science technology companies, pharmaceutical organizations, and healthcare innovators advancing biomarker-guided therapeutic development. Modern companion diagnostics combine molecular diagnostics, genomics, pathology, bioinformatics, artificial intelligence, and translational research into integrated platforms supporting personalized treatment decisions. Conventional diagnostic approaches frequently prove insufficient because targeted therapeutics increasingly require validated biomarkers capable of accurately identifying responsive patient populations before treatment initiation. Integrated companion diagnostic development therefore improves therapeutic precision while strengthening regulatory success. Demand is increasing because pharmaceutical companies continue expanding targeted therapeutics requiring companion diagnostics throughout clinical development and commercialization. Companion diagnostics increasingly support patient stratification, treatment selection, therapeutic monitoring, and regulatory approval across multiple disease areas. Pharmaceutical developers are strengthening partnerships with diagnostic manufacturers possessing advanced sequencing technologies, molecular testing platforms, computational biology expertise, and regulatory experience supporting global commercialization. The strategic importance of companion diagnostics extends beyond regulatory compliance into therapeutic differentiation, clinical trial optimization, healthcare efficiency, and personalized medicine adoption.

Market Drivers

Expanding Precision Medicine and Targeted Therapeutics

• Precision medicine increasingly depends on companion diagnostics that identify patients most likely to respond to targeted therapies, making biomarker-guided testing an essential component of pharmaceutical development. Demand is shifting toward integrated therapeutic-diagnostic development because regulatory agencies increasingly expect coordinated evidence supporting both therapeutic efficacy and diagnostic performance. Independent drug development frequently delays commercialization when biomarker validation remains disconnected from clinical development. Pharmaceutical companies are strengthening strategic collaborations with diagnostic manufacturers that combine molecular diagnostics, sequencing technologies, bioinformatics, and regulatory expertise into unified precision medicine programs. This transformation supports sustained expansion across the companion diagnostics competitive landscape.

Increasing Adoption of Next-Generation Sequencing

• Next-generation sequencing increasingly serves as the preferred technology supporting companion diagnostic development because targeted therapies require comprehensive genomic profiling across multiple biomarkers. Demand is increasing because conventional single-gene testing frequently fails to identify complex molecular alterations influencing treatment selection. Diagnostic developers increasingly invest in high-throughput sequencing platforms, cloud-based bioinformatics, and artificial intelligence-enabled genomic interpretation that strengthen analytical performance while supporting increasingly sophisticated precision medicine strategies. Technology innovation continues accelerating biomarker identification while improving commercialization opportunities across the companion diagnostics landscape.

Growing Pharmaceutical-Diagnostic Co-Development Models

• Companion diagnostics increasingly evolve alongside targeted therapeutics because coordinated development improves clinical trial efficiency, patient recruitment, and regulatory readiness. Pharmaceutical organizations continue expanding strategic partnerships with diagnostic developers because synchronized biomarker validation strengthens therapeutic differentiation and commercial success. Separate development programs frequently increase operational complexity and regulatory uncertainty throughout pharmaceutical development. Industry participants are integrating laboratory science, computational biology, and companion diagnostic development into unified innovation strategies that improve scientific coordination while accelerating commercialization. This integrated development model continues strengthening competitive dynamics throughout the market.

Rising Regulatory Support for Biomarker-Based Therapeutics

• Global regulatory agencies increasingly recognize companion diagnostics as essential tools supporting personalized medicine and biomarker-guided therapeutic development. Regulatory expectations continue evolving because targeted therapies increasingly require analytically validated diagnostics demonstrating clinical utility before market authorization. Pharmaceutical and diagnostic companies are strengthening regulatory planning, biomarker qualification, and clinical validation capabilities that improve submission quality while supporting global commercialization strategies. These developments continue driving long-term investment across companion diagnostic technologies.

Market Restraints

• Complex analytical and clinical validation requirements continue extending development timelines while increasing companion diagnostic development costs. Regulatory coordination across multiple jurisdictions continues creating commercialization challenges for globally marketed companion diagnostics. Integration of complex genomic testing into routine clinical workflows continues requiring specialized laboratory infrastructure, bioinformatics expertise, and healthcare provider education.

Technology and Segment Insights

By Technology

• Next-Generation Sequencing (NGS) continues gaining the largest strategic importance because precision medicine increasingly requires simultaneous evaluation of multiple genomic biomarkers supporting targeted therapeutic selection. Polymerase Chain Reaction (PCR) and digital PCR remain widely adopted because highly sensitive mutation detection continues supporting routine molecular testing across clinical laboratories. Immunohistochemistry (IHC) and In Situ Hybridization (ISH) continue maintaining strong demand because protein expression and tissue-based biomarker assessment remain essential for numerous oncology companion diagnostics. Immunoassays and other molecular technologies continue supporting diverse clinical applications.

By Therapeutic Area

• Oncology continues representing the dominant therapeutic segment because targeted cancer therapies increasingly require biomarker-guided patient selection prior to treatment initiation. Rare diseases and neurology are generating increasing diagnostic demand as genomic medicine expands personalized treatment approaches for genetically defined patient populations. Autoimmune diseases and infectious diseases continue strengthening companion diagnostic opportunities because precision therapeutics increasingly depend on molecular characterization and immune profiling. Cardiovascular diseases represent an additional area of growth.

By End User

• Pharmaceutical & Biotechnology Companies continue accounting for substantial demand because therapeutic development increasingly requires integrated diagnostic strategies supporting clinical trials and regulatory approval. Hospitals and Diagnostic Laboratories are expanding molecular testing infrastructure because personalized treatment increasingly depends on routine biomarker assessment during clinical practice. Academic & Research Institutes continue contributing scientific innovation through biomarker discovery, translational research, and clinical validation programs.

Competitive and Strategic Outlook

• The competitive landscape features major diagnostic and life science companies. Roche Diagnostics distinguishes itself through its fully integrated precision medicine strategy combining pharmaceutical development, molecular diagnostics, companion diagnostics, and digital pathology. QIAGEN N.V. differentiates itself through its expertise in molecular diagnostics, sample preparation, bioinformatics, and companion diagnostic development. Thermo Fisher Scientific Inc. distinguishes itself through its broad portfolio of genomics, proteomics, analytical instrumentation, and computational biology platforms. Agilent Technologies, Inc. differentiates itself through its expertise in molecular pathology, genomics, and tissue diagnostics. Illumina, Inc. distinguishes itself through its global leadership in next-generation sequencing and genomic analysis. Bio-Rad Laboratories, Inc. distinguishes itself through its expertise in digital PCR, molecular diagnostics, and immunoassays.
• Strategic developments include increasing integration of liquid biopsy and artificial intelligence, expansion of multi-biomarker companion diagnostics, and growth of pharmaceutical-diagnostic co-development models. Companies are forming strategic collaborations to strengthen biomarker validation, regulatory expertise, and global commercialization. Technology expansions focus on next-generation sequencing, digital pathology, and cloud-based bioinformatics. Companies that successfully integrate molecular diagnostics, computational biology, regulatory expertise, and global commercialization within scalable precision medicine platforms are expected to lead the market.

Conclusion

• The companion diagnostics competitive landscape is poised for significant growth, driven by the expansion of precision medicine, NGS adoption, and pharmaceutical-diagnostic co-development. The evolution toward integrated precision medicine ecosystems that combine pharmaceutical innovation, molecular diagnostics, and computational biology is reshaping the competitive landscape. Companies that successfully deliver comprehensive, clinically validated, and globally commercializable companion diagnostic solutions are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding precision medicine adoption will further accelerate development throughout the forecast period.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Competitive Benchmarking Methodology
• 2.4 Market Assessment Framework
• 2.5 Assumptions & Limitations

3. Companion Diagnostics Competitive Landscape Overview

• 3.1 Market Definition & Scope
• 3.2 Companion Diagnostics Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Competitive Trends
• 3.5 Historical Market Overview (2021-2025)
• 3.6 Competitive Outlook (2026-2035)
• 3.7 Precision Medicine Ecosystem
• 3.8 Companion Diagnostics Development Landscape
• 3.9 Co-Development Models Between Diagnostics and Therapeutics

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Next-Generation Sequencing (NGS) Innovation
• 6.3 Liquid Biopsy Innovation
• 6.4 AI & Bioinformatics Integration
• 6.5 Companion Diagnostic Pipeline Analysis
• 6.6 Multi-Omics Integration

7. Regulatory Landscape

• 7.1 Global Regulatory Framework
• 7.2 Companion Diagnostic Approval Pathways
• 7.3 Compliance Requirements

8. Companion Diagnostics Competitive Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Biomarker Type
• 8.3 Analysis by Therapeutic Area
• 8.4 Analysis by Regulatory Status
• 8.5 Analysis by Commercialization Strategy

9. Companion Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Technology
  • 9.1.1 Polymerase Chain Reaction (PCR)
  • 9.1.2 Next-Generation Sequencing (NGS)
  • 9.1.3 Immunohistochemistry (IHC)
  • 9.1.4 In Situ Hybridization (ISH)
  • 9.1.5 Digital PCR
  • 9.1.6 Immunoassays
  • 9.1.7 Other Technologies
• 9.2 By Therapeutic Area
  • 9.2.1 Oncology
  • 9.2.2 Neurology
  • 9.2.3 Infectious Diseases
  • 9.2.4 Autoimmune Diseases
  • 9.2.5 Rare Diseases
  • 9.2.6 Cardiovascular Diseases
  • 9.2.7 Other Therapeutic Areas
• 9.3 By End User
  • 9.3.1 Pharmaceutical & Biotechnology Companies
  • 9.3.2 Hospitals
  • 9.3.3 Diagnostic Laboratories
  • 9.3.4 Academic & Research Institutes

10. Companion Diagnostics Competitive Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Companion Diagnostics Competitive Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 China
• 11.7 Japan
• 11.8 South Korea
• 11.9 India
• 11.10 Australia

12. Competitive Landscape

• 12.1 Competitive Positioning Matrix
• 12.2 Market Share Analysis
• 12.3 Strategic Collaborations & Licensing Agreements
• 12.4 Mergers & Acquisitions
• 12.5 Product Launches & Regulatory Approvals

13. Company Profiles

• 13.1 Roche Diagnostics
• 13.2 QIAGEN N.V.
• 13.3 Thermo Fisher Scientific Inc.
• 13.4 Agilent Technologies, Inc.
• 13.5 Illumina, Inc.
• 13.6 Bio-Rad Laboratories, Inc.
• 13.7 Abbott Laboratories
• 13.8 Danaher Corporation (Cepheid & Leica Biosystems)
• 13.9 Revvity, Inc.
• 13.10 Guardant Health, Inc.
• 13.11 Foundation Medicine, Inc.
• 13.12 Exact Sciences Corporation
• 13.13 Myriad Genetics, Inc.
• 13.14 Standard BioTools Inc.
• 13.15 Sysmex Corporation

14. Companion Diagnostics Commercial Forecast Analysis

• 14.1 Forecast by Technology
  • 14.1.1 PCR
  • 14.1.2 NGS
  • 14.1.3 IHC
  • 14.1.4 ISH
• 14.2 Forecast by Therapeutic Area
  • 14.2.1 Oncology
  • 14.2.2 Infectious Diseases
  • 14.2.3 Rare Diseases
  • 14.2.4 Autoimmune Diseases
• 14.3 Forecast by End User
  • 14.3.1 Pharmaceutical & Biotechnology Companies
  • 14.3.2 Hospitals
  • 14.3.3 Diagnostic Laboratories

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 Corporate R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends